On March 9, 2022 Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biotechnology company, announced today that the company has completed the final Clinical Study Report (CSR) for their Phase 2 study of EC-18 in Chemoradiation-induced Oral Mucositis (CRIOM), entitled "Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of EC-18 in altering the severity and course of oral mucositis (OM) in subjects being treated with concomitant chemoradiation therapy for cancers of the mouth, oropharynx, hypopharynx, and nasopharynx (Press release, Enzychem Lifesciences, MAR 9, 2022, View Source [SID1234609817])."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The phase 2 U.S. study was designed as 2 stages with 105 randomized subjects at 21 sites to evaluate the safety, tolerability, and efficacy of its lead compound, EC-18 on mitigating severe oral mucositis (SOM) in head and neck subjects receiving concomitant chemoradiation therapy for cancers of the mouth, oropharynx, hypopharynx, and nasopharynx.

An iDSMB evaluated the safety endpoint every two weeks in a blinded fashion, until 30 days after the last dosing of Stage 1. If a safety issue was noted, the iDSMB was instructed to unblind the treatment assignments to ascertain if the adverse event (AE) was associated with the study drug. Since no safety issues were identified at the end of Stage 1, Stage 2 commenced using 2000 mg of the study drug, consistent with a positive safety outcome.

The primary efficacy endpoint demonstrated that the median duration of SOM (defined as WHO Grades 3 or 4) from baseline through short-term follow-up period (STFU) was 0.0 days in the EC-18 group versus 13.5 days in the placebo group (100% reduction).

The secondary efficacy endpoints showed that the incidence of SOM from baseline through the active treatment period was reduced by 37.1% in the EC-18 group when compared to the placebo group (40.9% vs. 65.0%). Similarly, the incidence of SOM from baseline through the STFU period also reported a reduction by 35.0% in comparison to the placebo group (45.5% vs. 70.0%). Based on the estimated median time to onset of SOM with a confidence interval of 95% utilizing the Kaplan Meier analysis, the time of onset of SOM was 8 days longer in the EC-18 group in comparison to the placebo group (43 days vs. 51 days). Also, EC-18 showed a median delay of 11.5 days in time to the first use of opioid analgesics when compared to the placebo group (37 days vs. 25.5 days).

On March 9, 2022 ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, reported the presentation of the design for its second phase III trial, COMPOSE (NCT04919226) at the 19th Annual European Neuroendocrine Tumor Society (ENETS) Conference being held in a hybrid format in Barcelona on March 10-11, 2022 (Press release, ITM Isotopen Technologien Munchen, MAR 9, 2022, View Source [SID1234609816]). The study is designed to evaluate the efficacy and safety of ITM’s lead radiopharmaceutical candidate, ITM-11 (n.c.a. 177Lu-edotreotide), compared to best standard of care for patients with well‐differentiated high grade 2 and grade 3 somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (G2+G3 SSTR+ GEP-NETs). ITM-11 is a Targeted Radionuclide Therapy consisting of the high-quality radioisotope, no-carrier-added lutetium-177 (n.c.a. 177Lu) combined with the somatostatin analogue edotreotide. The poster presentation follows the recent announcement of the first patient treated in the pivotal study.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"ITM is demonstrating its commitment to patients with neuroendocrine tumors expanding its clinical program through the COMPOSE trial with the aim of broadening therapeutic options for patients with high grade GEP-NETs. The potential role of ITM-11 in this area will enable a more personalized approach beyond chemotherapy," said Jorge Hernando, MD, PhD, Medical Oncologist, Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain and investigator for COMPOSE. "I am honored to be presenting ITM´s study design here in Barcelona at this year’s ENETS, the most important conference in the neuroendocrine tumors field in Europe – especially now, after two years of online meetings due to COVID-19."

"Our aspiration with COMPOSE is to demonstrate the value of ITM-11 in more advanced GEP-NET patient populations, as we strive to provide them with better treatment options," stated Steffen Schuster, CEO of ITM. "We value the opportunity to present our second phase III trial to the expert ENETS community as we continue advancing our lead candidate through the clinic."

COMPOSE is an international, prospective, randomized, controlled, open-label, multi-center phase III study to evaluate the efficacy, safety, and patient-reported outcomes of first or second-line treatment with ITM-11 compared to best standard of care in patients with well-differentiated high grade 2 and grade 3 (Ki-67 index 15-55), SSTR+, GEP-NETs. The study aims to randomize 202 patients 1:1 to ITM-11 or best standard of care — either chemotherapy (CAPTEM or FOLFOX) or everolimus — according to the investigator’s choice. The primary endpoint of the study is progression-free survival (PFS), which will be assessed every 12 weeks from randomization onwards. Secondary outcome measures include overall survival (OS) up to two years after disease progression. COMPOSE builds upon ITM’s first ongoing phase III clinical trial, COMPETE (NCT03049189), examining patients with grade 1 and grade 2, GEP-NETs. ITM’s subsidiary, ITM Solucin GmbH is the sponsor of both studies.

Presentation information

Title: COMPOSE: Phase III Trial of 177Lu-edotreotide versus Standard of Care in Well-differentiated (WD) Aggressive Grade 2 and Grade 3 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Abstract No: #3389

Poster No: M03

Session: Phase III Clinical Trials in Progress

Presenter: Jorge Hernando, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain

About Targeted Radionuclide Therapy

Targeted Radionuclide Therapy is an emerging class of cancer therapeutics, which seeks to deliver radiation directly to the tumor while minimizing radiation exposure to normal tissue. Targeted radiopharmaceuticals are created by linking a therapeutic radioisotope to a targeting molecule (e.g., peptide, antibody, small molecule) that can precisely recognize tumor cells and bind to tumor-specific characteristics, like receptors on the tumor cell surface. As a result, the radioisotope accumulates at the tumor site and decays, releasing a small amount of ionizing radiation, thereby destroying tumor tissue. The highly precise localization enables targeted treatment with minimal impact to healthy surrounding tissue.

About ITM-11 (n.c.a. 177Lu-edotreotide)

ITM-11, ITM’s therapeutic radiopharmaceutical candidate being investigated in the phase III clinical studies COMPETE and COMPOSE, consists of two components: the medical radioisotope no-carrier-added lutetium-177 (n.c.a. 177Lu) and the targeting molecule edotreotide, a synthetic form of the peptide hormone somatostatin that targets neuroendocrine tumor-specific receptors. Edotreotide binds to these receptors and places the medical radioisotope n.c.a. lutetium-177 directly onto the diseased neuroendocrine cells so that it accumulates at the tumor site. N.c.a. lutetium-177 is internalized into the tumor cells and decays, releasing medical radiation (ionizing β-radiation) with a maximum radius of 1.7 mm and destroying tumor tissue.

On March 9, 2022 Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of oncolytic immune-therapeutics based on Seneca Valley Virus (SVV-001), reported the publication of an abstract "Oncolytic Seneca Valley Virus (SVV-001) overcomes checkpoint inhibitor resistance and demonstrates a systemic anti-tumor immune response in a syngeneic pancreatic cancer murine model" at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) meeting in New Orleans, LA (Press release, Seneca Therapeutics, MAR 9, 2022, View Source [SID1234609815]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract will be presented by Dr. Paul Hallenbeck, one of the authors of the publication. The permanent abstract number is #6218. The presentation will be available starting April 8.

On March 9, 2022 Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, reported plans to present at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, held in New Orleans and virtually from April 8-13, 2022 (Press release, Boundless Bio, MAR 9, 2022, View Source [SID1234609814]). The in-person poster presentation reveals a novel association between ecDNA bearing tumors and high replication stress, presenting a potential therapeutic strategy for ecDNA-enabled oncogene amplified cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details:

Title: Replication stress and the inability to repair damaged DNA, the potential "Achilles’ heel" of ecDNA+ tumor cells
Session Title: Genomic Instability 2
Abstract Number: 1520
Date and Time: April 11, 2022, 1:30 p.m. – 5:00 p.m. ET
Location: Poster Section 5

About ecDNA

Extrachromosomal DNA ("ecDNA") are circular units of nuclear DNA found within cancer cells, and which contain highly transcriptionally active genes, including oncogenes, but are physically distinct from chromosomes and lack centromeres. ecDNA replicate within cancer cells and, due to their lack of centromeres, can be asymmetrically passed to daughter cells during cell division, leading to focal gene amplification and copy number heterogeneity in cancer. By leveraging the plasticity afforded by ecDNA, cancer cells have the ability to increase or decrease copy number of select oncogenes located on ecDNA to enable survival under selective pressures, including targeted therapy, immunotherapy, chemotherapy, or radiation, thereby making ecDNA one of cancer cells’ primary mechanisms of growth, recurrence, and treatment resistance. ecDNA are not found in healthy cells but are present in many solid tumor cancers. They are a key driver of the most aggressive and difficult-to-treat cancers, specifically those characterized by high copy number amplification of oncogenes.

On March 9, 2022 Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, reported that management will present virtually at the Oppenheimer 32nd Annual Healthcare Conference on Wednesday, March 16, 2022 at 4:00 p.m. ET (Press release, Wugen, MAR 9, 2022, View Source [SID1234609813]). The presentation will be available to registered conference attendees.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!